Home > Press > NanoMed, Inc. Spins Out of Zyvex Labs
Abstract:
Zyvex Labs today announced its first company spinout: NanoMed, Inc. The new company was started by Rob Burgess, PhD, former Vice President of Research & Development at Zyvex Instruments, and Gareth Hughes, PhD, former Group Leader of Life Sciences at Zyvex Corporation.
NanoMed is focused on the application of nanotechnology in Life Sciences. The company seeks to apply nanoparticle technologies for the development of research grade reagents and cutting-edge therapeutics. In addition, NanoMed possesses a strong collection of nanotechnology platforms that are currently available for licensing. The new company leverages Zyvex's existing Life Science patents, proprietary methods, and core technologies.
"We are delighted to obtain assignment of the nanoparticle dispersion intellectual property from Zyvex Labs," said Rob Burgess, Ph.D., NanoMed's Co-Founder and Chairman of the Board. "The application of Zyvex Performance Materials' Kentera(TM) and other polymers for functionalizing carbon nanotubes will play an integral role in solidifying NanoMed's portfolio of cutting-edge nanotechnologies as they relate to the biomedical sciences. We look forward to continuing a productive partnership with Zyvex Labs and Zyvex Performance Materials."
"Rob is a focused leader with outstanding technology development skills," said Zyvex Founder Jim Von Ehr. "He also has a proven track record in growing businesses. I expect to see exciting new products from this new venture."
NanoMed's focus centers around the functionalization and specific delivery of nanoparticles for applications in various biomedical markets, including the research, diagnostics, therapeutics, and veterinary sectors. In collaboration with their strategic partners, NanoMed researchers have developed promising technologies that will allow for the effective use of nanotechnology-based solutions to address a variety of issues across multiple scientific disciplines, including basic biomedical research and applied science related to disorders such as cancer and infectious diseases.
Other founders include Rocky Draper, PhD, Professor at the University of Texas at Dallas, and Ellen Vitetta, PhD, Professor and Director of the Cancer Immunobiology Center at the University of Texas Southwestern Medical Center in Dallas.
More information about NanoMed's technologies and business strategy can be found at http://www.nanomedinc.com/ .
####
For more information, please click here
Contacts:
NanoMed Incorporated
P.O. Box 850922
Richardson, Texas 75085-0922
United States
ph: 951-970-8525
fax: 214-440-2311
Copyright © PR Newswire Association LLC.
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
Nanomedicine
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Acquisitions/Mergers/Splits
180 Degree Capital Corp. Life Science Portfolio Company Enters Into Definitive Agreement to be Acquired May 6th, 2020
180 Degree Capital Corp.’s Portfolio Company, Synacor, Inc., Agrees to Merge with Qumu Corporation in All-Stock Transaction February 11th, 2020
Combination of Nanometrics and Rudolph Technologies to Create Onto Innovation October 16th, 2019
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||